Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET.
Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company's strategic execution, commercial momentum, and capital discipline across its key growth platforms.
On the back of robust performance in H1 2025, Cosmo has raised its full-year EBITDA guidance by €4.5 million and reconfirmed its total revenue outlook for 2025, while confirming double-digit growth in recurring revenues – driven by its leading products and technologies in MedTech AI and Dermatology.
H1 2025 Highlights
Cosmo delivered strong financial and operational performance in the first half of 2025, with strong momentum in GI Genius™ and Winlevi®, continued cost discipline, and a strong balance sheet.
Total Revenues: €51.7 million
€41.9 million in recurring revenues
€9.8 million in project-based revenues
Growth Drivers:
GI Genius™ recurring revenues: +128% YoY
Winlevi® recurring revenues: +23% YoY
Operating Expenses: €57.8 million
Cost of Sales: €25.6 million (+10% YoY)
R&D: €18.0 million (–6% YoY)
SG&A: €14.3 million (–13% YoY)
Cash, Equivalents, and Investments: €133.3 million as of June 30, 2025
Treasury Shares: 1.6 million shares held as of June 30, 2025 (~€97.7 million), an increase of 76.2K shares vs. December 31, 2024
H2 2025 Outlook
Cosmo expects continued momentum in the second half of 2025, with:
Recurring revenues: €43 – 48 million
Continued triple digit growth from GI Genius®, double digit growth from Winlevi® and steady growth from Gastro and CDMO business.
Increased R&D spending to advance Phase II programs for Bile Acid Diarrhoea and Distal Ulcerative Colitis.
Continued SG&A discipline to drive margin expansion
Strategic Context
Cosmo operates at the intersection of high-growth global markets — AI in endoscopy, Dermatology, Gastrointestinal diseases, and advanced Drug Manufacturing.
Each of these sectors is fuelled by large, persistent clinical unmet needs:
In MedTech AI, Cosmo's GI Genius™ is redefining detection and diagnostic accuracy in real time.
In Dermatology, Winlevi® is the first new acne mechanism of action in decades.
In Gastroenterology, Cosmo's Phase II pipeline addresses conditions like Bile Acid Diarrhoea and distal ulcerative colitis.
In CDMO, Cosmo supports global pharmaceutical partners with advanced formulation, regulatory, and sterile manufacturing expertise.
What makes Cosmo unique is its ability to scale innovation across all four businesses — leveraging common R&D infrastructure, regulatory know-how, Artificial Intelligence, Digital capabilities, and manufacturing excellence. This integrated model is designed to unlock operational leverage, reduce time-to-market, and drive compounding long-term growth.
Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented:
'These results validate our strategy: we are scaling impact across high-need therapeutic areas with real momentum. What sets Cosmo apart is our ability to operate as one company with four powerful platforms: AI-powered MedTech, next-generation Dermatology, GI innovation, and high-value CDMO. These aren't isolated businesses, they reinforce each other, creating a scalable ecosystem with clinical, operational, and financial synergies. We're not just growing — we're compounding. And this is just the beginning of our 2030 vision.'
Svetlana Sigalova, Chief Financial Officer of Cosmo, added:
'Our first-half results reflect strong execution, continued growth in recurring revenues, and prudent financial management. We remain disciplined in controlling costs and investing where it matters most. With a solid balance sheet and clear capital priorities, we're well positioned to support Cosmo's long-term growth and deliver on our 2030 ambition.'
Analyst, media and investors call today at 2 pm CET
Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow today at 2:00 pm CET.
To join via Web browser, click here
To join via phone, please use one of the following dial-in numbers:
Switzerland/Europe +41 (0) 58 310 50 00
United Kingdom +44 (0) 207 107 06 13
United States +1 (1) 631 570 56 13
Key figures
EUR 1'000
H1 2025
H1 2024
(restated)
Income statement
Revenue
51,720
136,237
Recurring Revenues
41,925
42,379
Project Based Revenues
9,795
93,858 [1]
Cost of sales
(25,571)
(23,150)
Gross profit
26,149
113,087
Other income
4,701
1,122
R&D costs
(17,997)
(19,137)
SG&A costs
(14,264)
(16,323)
Net operating expenses
(27,560)
(34,338)
Operating profit/(loss)
(1,411)
78,749
Net financial income
741
1,794
Profit/(loss) before taxes
(670)
80,543
Profit/(loss) after taxes for the period
(2,030)
71,177
EBITDA
4,852
84,868
Statement of financial position
As of 30 June 2025
As of 31 December 2024
Non-current assets
423,104
444,514
Cash and cash equivalents
50,749
44,296
Other current assets
136,477
157,962
Liabilities
143,354
141,681
Equity attributable to owners of the Company
460,239
498,330
Non-controlling interests
6,737
6,761
Equity ratio (%)
75.4%
77.0%
Shares
H1 2025
H1 2024
(restated)
Weighted average number of shares
15,970,541
16,105,126
Earnings/(loss) per share (in EUR)
(0.126)
4.423
The full Half-Year 2025 Report of Cosmo can be found for download as pdf-document on the Company's website via https://www.cosmopharma.com/investors/financial-reports
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit https://www.cosmohealthconfidence.com
Financial calendar
Attachments
PDF - English
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
Speeding up generic drug approval timelines a priority, health minister says
The federal government is committed to speeding up drug approval timelines as part of Prime Minister Mark Carney's drive to improve efficiency and cut red tape, Health Minister Marjorie Michel said in an interview. The Globe and Mail reported this week on new data that showed Health Canada is increasingly failing to review generic drug applications within its 180-day target, meaning cheaper pharmaceuticals are taking longer to get to market. That is on top of Canada's historically slow timelines for all drugs, which rank among the longest in developed countries. Ms. Michel said that, while safety can't be compromised, it is clear there are ways to make the approval process more efficient and she has asked her department to report to her regularly on timelines. 'It's a priority for me,' she said in an interview Tuesday. Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers The Liberals promised in the spring election to 'significantly reduce' wait times for pharmaceuticals, which it acknowledged were longer than in other Group of Seven countries. 'By cutting red tape without compromising on safety we will cut this timeline while maintaining all relevant safety standards, supporting our research community and delivering life-saving medicines more quickly,' the Liberal campaign platform said. Health Canada has said one reason for delays in generics applications is incomplete or inadequate documentation from pharmaceutical companies. Data reported by The Globe this week showed that, in the 2024-25 fiscal year, 70 per cent of applications received a ruling in the final week before the 180-day target. In about three-quarters of those cases, the applications were rejected and Health Canada requested further information. But 90 per cent of applications were ultimately approved, leading the Canadian Generic Pharmaceutical Association, which represents generic drug makers, to argue that the early rejections are more a sign of files being picked up too late and not because of underlying deficiencies with the drugs. Ms. Michel said one relatively straightforward solution is earlier screening of applications. 'Where I can push is, yeah, we cannot take eight months to let them know' when there are paperwork issues, she said. 'If work has to be done, then the person needs to know as soon as possible.' Sandoz to reportedly offer generic weight-loss drugs in Canada at up to 70% discount Another area of improvement the minister identified is better collaboration with regulators in other countries. Most large pharmaceutical companies operate globally and have to work with regulators in other countries. They often question why Canadian regulators take longer than European peers. 'I would say also that what I'm encouraging my department to do a lot is to lean on approvals done by like-minded partners,' Ms. Michel said. 'Because if a drug is approved somewhere, we trust that [they] have the same regulations than we have or quite the same, well, maybe it can speed up the process.' Not all parts of the drug approval process are under federal control. The final stage of the pathway is when drug makers go to the pan-Canadian Pharmaceutical Alliance to negotiate pricing deals with all federal, provincial and territorial public insurance plans. In those discussions, Ottawa is one of 14 seats at the table. Ms. Michel said she is working with provincial counterparts on this issue, although it is one of many urgent health problems the system is facing. 'You know, they are overwhelmed, maybe with primary care,' she said of the provinces, adding that it is her role to bring everyone to the table and 'see how we can, you know, speed the process.' She said one of Canada's major strengths is its research sector. She said that will continue to be a focus and pointed to an announcement of $1.3-billion in research funding she and Industry Minister Mélanie Joly made in July. 'We have to deliver on this,' she said.
Globe and Mail
an hour ago
- Globe and Mail
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.95 in the second quarter of 2025, up 13.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.3%. GAAP EPS for the quarter was $2.58, reflecting an uptick of 3.2% year over year. DaVita's Revenues in Detail Revenues of $3.38 billion in the second quarter increased 6.1% year over year. The figure topped the Zacks Consensus Estimate by 1.3%. Revenue per treatment in the second quarter of 2025 was $404.6 million, up 3.7% year over year and 1.1% sequentially. Per management, this was primarily driven by normal seasonal improvements, including patients meeting their co-insurance and deductibles. This was partially offset by decreased volume of phosphate binders. Shares of this company plunged nearly 10.1% till last trading. DVA's Segment Details DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues. The dialysis patient service revenues were $3.21 billion, up 4.8% year over year. Other revenues were $172.7 million, up 37.4% from the year-ago quarter's figure. Per management, the total U.S. dialysis treatments for the second quarter were 7,186,217 or 92,131 per day, on average. This represents a per-day increase of 0.4% on a sequential basis. Normalized non-acquired treatment declined 0.8% year over year in the second quarter of 2025. As of June 30, 2025, DaVita provided dialysis services to around 283,100 patients at 3,175 outpatient dialysis centers, of which 2,662 were U.S. centers while 513 were located across 13 other countries. During the second quarter of 2025, the company acquired one, opened three and closed two dialysis centers in the United States. It also opened six and closed five dialysis centers outside the United States in the same period. As of June 30, 2025, DaVita had approximately 64,400 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.3 billion in annualized medical spend. The company also had an additional 9,300 patients in other integrated care arrangements. DaVita's Margin Details In the quarter under review, DaVita's gross profit increased 7% year over year to $1.12 billion. The gross margin expanded 31 basis points (bps) to 33.1%. General & administrative expenses climbed 12.2% year over year to $412.8 million. Adjusted operating profit totaled $705.2 million, reflecting a 4.2% increase from the prior-year quarter's level. Adjusted operating margin in the second quarter contracted 36 bps to 20.9%. DVA's Financial Position DaVita exited second-quarter 2025 with cash and cash equivalents and short-term investments of $739.4 million compared with $511.9 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2025 was $10.26 billion compared with $9.74 billion at the first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter 2025 was $504.2 million compared with $664 million a year ago. During the three months ended June 30, 2025, DVA repurchased 3.1 million shares for $446 million. DaVita's Guidance DaVita has reiterated its adjusted EPS outlook for 2025. Adjusted EPS for the full year is continued to be projected in the range of $10.20-$11.30. The Zacks Consensus Estimate currently stands at $10.76. Our Take on DVA DaVita ended the second quarter of 2025 with better-than-expected results. The uptick in the company's top and bottom lines and revenue per treatment was encouraging. The per-day increase in total U.S. dialysis treatments for the second quarter on a sequential basis and solid revenues from both sources were encouraging. The opening and acquiring of dialysis centers within the United States and acquiring centers overseas were promising. The gross margin expansion bodes well for the stock. However, the year-over-year decline in normalized non-acquired treatment was disappointing. The contraction of the adjusted operating margin does not bode well for the stock. DaVita's Zacks Rank and Key Picks DVA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
Can AngloGold Ashanti Maintain Its EBITDA Margin Expansion Streak?
AngloGold Ashanti plc AU delivered an impressive 111% increase in adjusted EBITDA to $1.4 billion in the second quarter of 2025. This was boosted by higher production volumes, cost discipline and elevated gold prices. The adjusted EBITDA margin expanded to 59% in the quarter from 50% in the year-ago quarter. This followed an impressive first quarter, where adjusted EBITDA surged 158% to $1.12 billion. AngloGold Ashanti has generated a total of $2.56 billion in adjusted EBITDA in the first half of 2025. A key driver of this performance is the company's Full Asset Potential Program, which has been driving cost efficiencies and insulating operations against inflation. The impact of this program was already visible in 2024, when adjusted EBITDA rose 93%, recovering from a 21% decline in 2023. AngloGold Ashanti's gold production was up 22% year over year to 1.52 million ounces in the first half of 2025. This was bolstered by contributions from the recently acquired Sukari Gold Mine in Egypt, along with improved performances at key assets, including Obuasi, Siguiri, Geita and Cerro Vanguardia. For 2025, AngloGold Ashanti projects gold production of 2.9-3.225 million ounces, indicating 9–21% growth over the prior year. Higher production, the rally in gold prices this year and its ongoing cost control efforts position the company for further EBITDA gains in the months ahead. While AngloGold Ashanti's EBITDA performance was driven by both volume and margin expansion, peers Newmont Corporation NEM and Agnico Eagle Mines AEM saw improved EBITDA in their recently reported results, mainly due to favorable gold prices. Newmont reported a 52% year over year surge in adjusted EBITDA to around $3 billion in the second quarter of 2025 with adjusted EBITDA margin compared with 45% in the year-ago quarter. Newmont attributed the increase to higher net income driven by higher prices, which offset the impact of lower production. Agnico Eagle Mines reported an adjusted EBITDA of $1.9 billion in the second quarter of 2025, which marked a 63% year-over-year jump. The rise in adjusted EBITDA reflected increased mine operating margins from higher realized gold prices that helped partially offset lower gold sales, increased production costs and higher general and administrative expenses. Agnico Eagle Mine's adjusted EBITDA margin stood at 68% in the second quarter compared with 57% in the year-ago quarter. AU's Price Performance, Valuations & Estimates AngloGold Ashanti's stock has skyrocketed 144.6% year to date, outperforming the Zacks Mining – Gold industry's 63.7% growth. During this time, the Basic Materials sector has risen 10.3% and the S&P 500 has rallied 7.4%. AU is currently trading at a forward 12-month earnings multiple of 11.41X, a discount to the industry average of 12.87X. The Zacks Consensus Estimate for AngloGold Ashanti's 2025 sales is $8.85 billion, indicating 52.8% year-over-year growth. The consensus mark for the year's earnings is $4.99 per share, indicating year-over-year growth of 125.8%. The Zacks Consensus Estimate for 2026 sales implies 2.3% year-over-year growth. The same for earnings, however, indicates a decline of 1.3%. EPS estimates for 2025 and 2026 have been trending south over the past 60 days, as seen in the chart below. AU currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Newmont Corporation (NEM): Free Stock Analysis Report AngloGold Ashanti PLC (AU): Free Stock Analysis Report Agnico Eagle Mines Limited (AEM): Free Stock Analysis Report
